In Response
- PMID: 38771608
- DOI: 10.1213/ANE.0000000000006983
In Response
References
-
- Horvath B, Saadat H, Kloesel B. Cannabis hyperemesis syndrome: perioperative concern with potential paradoxical response to propofol. Anesth Analg. 2024;138:e38–e39.
-
- Gajendran M, Sifuentes J, Bashashati M, McCallum R. Cannabinoid hyperemesis syndrome: definition. J Investig Med. 2020;68:1309–1316.
-
- Sun HJ, Lu Y, Wang HW, et al. Activation of endocannabinoid receptor 2 as a mechanism of propofol pretreatment-induced cardioprotection against ischemia-reperfusion injury in rats. Oxid Med Cell Longev. 2017;2017:2186383.
-
- Parekh JD, Wozniak SE, Kham K, et al. Cannabinoid hyperemesis syndrome. BMJ Case Rep. 2016;0:2016.
-
- Ruberto AJ, Sivilotti MLA, Forrester S, Hall AK, Crawford FM, Day AG. Intravenous haloperidol versus ondansetron for cannabis hyperemesis syndrome (HaVOC): a randomized, controlled trial. Ann Emerg Med. 2021;77:613–619.
Publication types
LinkOut - more resources
Full Text Sources